A Case of Successful Third Renal Transplantation Using Rituximab (anti-CD20 Monoclonal Antibody) in a Highly Sensitized Patient.
- Author:
Su Jin MOON
1
;
Su Hyun KIM
;
Hye Eun YOON
;
Yong Kyun KIM
;
Bum Soon CHOI
;
Chul Woo YANG
;
Yong Soo KIM
;
Byung Kee BANG
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. yangch@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Rituximab;
Graft rejection;
Renal transplantation
- MeSH:
Adult;
Graft Rejection;
Humans;
Immunoglobulins;
Kidney Transplantation*;
Lymphoma, Non-Hodgkin;
Male;
Plasmapheresis;
Reference Values;
Rituximab
- From:Korean Journal of Nephrology
2007;26(5):646-650
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Rituximab, chimeric murine/human anti-CD20 monoclonal antibody, has been currently used as treatment of follicular non-Hodgkins lymphoma and posttransplantation lymphoproliferative disease. Nowadays, rituximab has also been utilized in the renal transplantation to get over acute rejection in highly sensitized patients. We hereby report a case of successful renal transplantation in a highly sensitized patient, who has been done the 3rd renal transplantation. A 44-year-old male patient admitted for the 3rd renal transplantation. His previous 2 transplantations failed because of acute rejection. We tried plasmapheresis and intravenous immunoglobulin, widely used as pretransplantation management in high risk patients. In addition to these, we applied 2 times of rituximab (375 mg/m2) before transplantation at interval of 1 week. The renal function of the patient has been within the normal range without any evidence of rejection 6 months after transplantation.
